ETON supply chain intelligence for Eton Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Eton Pharmaceuticals, Inc. (ETON) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AMMTEK | AMMTEK | 92% | In July 2025 , the Company paid $ 500 to AMMTek upon the receipt of FDA meeting minutes and under the terms of the licensing agreement, the Company could pay up to $1,850 as follows: $ 550 upon NDA a… |
| IPSEN-S-A | IPSEN-S-A | 92% | In December 2024 , the Company acquired INCRELEX® (mecasermin injection) from Ipsen S.A. The Company is obligated to pay the seller $ 2,500 on each of the first and second anniversaries of closing, o… |
| KNIGHT-THERAPEUTICS-INC | KNIGHT-THERAPEUTICS-INC | 92% | Eton Pharmaceuticals, Inc. entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules with an affiliate of Knight Therape… |
| PIERRE-FABRE | PIERRE-FABRE | 92% | In February 2026, the Company entered into a licensing agreement to acquire the U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre. |
| PIERRE-FABRE-MEDICAMENT-SAS | PIERRE-FABRE-MEDICAMENT-SAS | 92% | The Company will also purchase approximately $1.5 million of inventory at closing and an estimated $0.7 million of inventory in May 2026. |
| SWK-FUNDING-LLC | SWK-FUNDING-LLC | 92% | On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC ("SWK"). |
| TEVA-PHARMACEUTICALS-USA-INC | TEVA-PHARMACEUTICALS-USA-INC | 92% | In December 2024 , the Company acquired GALZIN® (zinc acetate) from Teva Pharmaceuticals USA, Inc and assumed the commercialization of the product in the U.S. during March of 2025 . |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: x’s customer base has grown to include more than 10,000 U.S. eyecare-dedicated prescribers and institutions. 5 Pharmaceutical Compounding Pharmaceutical compo… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | Reciprocal relationship from NBIX graph: Reciprocal relationship from ETON graph: Reciprocal relationship from NBIX graph: cules, peptides, proteins, antibodies, and gene therapy. We launched INGREZZ… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ETON graph: nd of the years below is as follows: $ $ Gross increases (decreases) related to prior year positions Gross increases… |
| ORANY | ORANY | 72% | nd of the years below is as follows: $ $ Gross increases (decreases) related to prior year positions Gross increases (decreases) related to current year positions Decreases related to settlements wit… |
| SWKHL | SWKHL | 72% | million increase in G&A expenses was primarily due to personnel additions to support our growing business as well as marketing spend on new products. We incurred a net loss of $3.8 million and $0.9 m… |
| SWKHL | SWKHL | 72% | Reciprocal relationship from SWKHL graph: Reciprocal relationship from ETON graph: million increase in G&A expenses was primarily due to personnel additions to support our growing business as well as… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ANOVORX | ANOVORX | 92% | The Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx for the Company's INCRELEX®, HEMANGEOL®, ALKINDI SPRINKLE®, KH… |
| PENTEC-HEALTH | PENTEC-HEALTH | 92% | The Company's revenues and its accounts receivable balances are highly concentrated and consist of sales to and amounts due from AnovoRx for the Company's INCRELEX®, HEMANGEOL®, ALKINDI SPRINKLE®, KH… |
| HROW | Harrow, Inc. | 72% | Reciprocal relationship from HROW graph: Reciprocal relationship from ETON graph: Reciprocal relationship from HROW graph: Reciprocal relationship from ETON graph: Reciprocal relationship from HROW g… |
| MNPR | Monopar Therapeutics Inc. | 72% | Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ETON graph: nd of the years below is as follows: $ $ Gross increases (decreases) related to prior year positions Gross increases… |
| ORANY | ORANY | 72% | nd of the years below is as follows: $ $ Gross increases (decreases) related to prior year positions Gross increases (decreases) related to current year positions Decreases related to settlements wit… |
| SWKHL | SWKHL | 72% | Reciprocal relationship from SWKHL graph: Reciprocal relationship from ETON graph: Reciprocal relationship from SWKHL graph: Reciprocal relationship from ETON graph: Reciprocal relationship from SWKH… |
| SWKHL | SWKHL | 72% | million increase in G&A expenses was primarily due to personnel additions to support our growing business as well as marketing spend on new products. We incurred a net loss of $3.8 million and $0.9 m… |
| LUKARE-MEDICAL-LLC | LUKARE-MEDICAL-LLC | 62% | unts) (Unaudited) Note 11 — Related-Party Transactions Chief Executive Officer Previously, the Company acquired DS- 200 and all related intellectual property pursuant to an asset purchase agreement (… |
| MESSA-HOLDINGS-LLC | MESSA-HOLDINGS-LLC | 62% | unts) (Unaudited) Note 11 — Related-Party Transactions Chief Executive Officer Previously, the Company acquired DS- 200 and all related intellectual property pursuant to an asset purchase agreement (… |
| SWK-FUNDING-LLC | SWK-FUNDING-LLC | 62% | Cost of product sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products from third -party manufac… |
| TEVA-PHARMACEUTICALS-USA-INC | TEVA-PHARMACEUTICALS-USA-INC | 62% | 5,000 based on the achievement of certain future development and commercial milestones related to DS- 200 , of which the Company would recognize 45 % of the proceeds from the future milestones, with … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ETON-DEBT-9375 | Warrants outstanding: 359116 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| ETON-DEBT | Debt stack $27.9M | 90% | Market cache reports total debt of $27.9M. |
| ETON-DEBT-9376 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2018-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ETON-OWNER-OPALEYE-MANAGEMENT-INC | Opaleye Management Inc. | 90% | 13F overlay lists Opaleye Management Inc. as top holder; 116 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | 100.00 | 2 | |
| SWKHL | SWK Holdings Corp | 100.00 | 1 | ['customer', 'supplier'] |
| SLNO | Soleno Therapeutics, Inc. | 100.00 | 2 | |
| VYGR | Voyager Therapeutics, Inc. | 100.00 | 2 | |
| HROW | Harrow, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| AARD | Aardvark Therapeutics, Inc. | 100.00 | 2 | |
| STQN | Strategic Acquisitions, Inc. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 2 | |
| LXEO | Lexeo Therapeutics, Inc. | 100.00 | 2 | |
| MPLT | MapLight Therapeutics, Inc. | 100.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| CNOB | ConnectOne Bancorp, Inc. | 50.00 | 2 | |
| EQR | Equity Residential | 50.00 | 2 | |
| D | Dominion Energy, Inc. | 50.00 | 2 | |
| FENC | Fennec Pharmaceuticals Inc. | 50.00 | 2 | |
| CLNE | Clean Energy Fuels Corp. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CHUC | Charlie's Holdings, Inc. | 50.00 | 2 |